Helsinn and MGI Pharma announce sNDA for ALOXI Capsules accepted for review by U.S. FDA
LUGANO, Switzerland and MINNEAPOLIS, MN (ots) - Helsinn Healthcare S.A., Switzerland, a privately owned pharmaceutical group and its partner, MGI Pharma (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Capsules for oral ...